Skip to main content
Top
Published in: Journal of Gastroenterology 2/2020

01-02-2020 | Fatty Liver | Original Article—Liver, Pancreas, and Biliary Tract

Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients

Authors: Kenichiro Enooku, Takeya Tsutsumi, Mayuko Kondo, Naoto Fujiwara, Takayoshi Sasako, Junji Shibahara, Akira Kado, Kazuya Okushin, Hidetaka Fujinaga, Ryo Nakagomi, Tatsuya Minami, Masaya Sato, Koji Uchino, Hayato Nakagawa, Yuji Kondo, Yoshinari Asaoka, Ryosuke Tateishi, Kohjiro Ueki, Hitoshi Ikeda, Haruhiko Yoshida, Kyoji Moriya, Hiroshi Yotsuyanagi, Takashi Kadowaki, Kazuhiko Koike

Published in: Journal of Gastroenterology | Issue 2/2020

Login to get access

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are characterized by the accumulation of excess hepatic fat. However, in the progression from NASH to cirrhosis, hepatic fat is often lost. Our aim was to elucidate the mechanism underlying hepatic fat loss during NASH progression.

Methods

Liver biopsies were performed at The University of Tokyo Hospital between November 2011 and March 2016 on 146 patients with NAFLD and 14 patients with cryptogenic cirrhosis who were not being treated with any diabetes or dyslipidemia drugs. Among them, 70 patients underwent liver biopsy after an overnight fast, and 90 patients were biopsied 5 h after an oral glucose tolerance test. Expression differences in genes encoding several fatty acid metabolism-related factors were examined and correlated with hepatic histological changes based on NAFLD activity scores. Prospective patient follow-up continued until June 2018.

Results

The level of fatty acid transport protein 5 (FATP5), which is associated with free fatty acid intake, was significantly and inversely correlated with features of histological progression, including ballooning and fibrosis. This was confirmed by immunohistochemical analysis. Transcript levels of genes encoding fatty acid metabolism-related proteins were comparable between NASH with severe fibrosis and cryptogenic cirrhosis. Furthermore, a prospective cohort study demonstrated that low FATP5 expression was the most significant risk factor for hepatic fat loss.

Conclusions

Decreased hepatic FATP5 expression in NAFLD is linked to histological progression, and may be associated with hepatic fat loss during NASH progression to cirrhosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.PubMed Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.PubMed
2.
go back to reference Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name. J Hepatol. 2018;68:391–2.PubMed Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name. J Hepatol. 2018;68:391–2.PubMed
3.
go back to reference Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8:346–52.PubMedPubMedCentral Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8:346–52.PubMedPubMedCentral
4.
go back to reference Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136–43.PubMed Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136–43.PubMed
5.
go back to reference Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig. 2005;115:1343–51.PubMedPubMedCentral Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig. 2005;115:1343–51.PubMedPubMedCentral
6.
go back to reference Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med. 2007;24:934–45.PubMed Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med. 2007;24:934–45.PubMed
7.
go back to reference Gambino R, Bugianesi E, Rosso C, et al. Different serum free fatty acid profiles in NAFLD subjects and healthy controls after oral fat load. Int J Mol Sci. 2016;17:479.PubMedPubMedCentral Gambino R, Bugianesi E, Rosso C, et al. Different serum free fatty acid profiles in NAFLD subjects and healthy controls after oral fat load. Int J Mol Sci. 2016;17:479.PubMedPubMedCentral
8.
go back to reference Zhang J, Zhao Y, Xu C, et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014;4:5832.PubMedPubMedCentral Zhang J, Zhao Y, Xu C, et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014;4:5832.PubMedPubMedCentral
9.
go back to reference Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol. 2006;290:G194–98.PubMed Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol. 2006;290:G194–98.PubMed
10.
go back to reference Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.PubMed Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.PubMed
11.
go back to reference Schneider H, Staudacher S, Poppelreuther M, et al. Protein mediated fatty acid uptake: synergy between CD36/FAT-facilitated transport and acyl-CoA synthetase-driven metabolism. Arch Biochem Biophys. 2014;546:8–18.PubMed Schneider H, Staudacher S, Poppelreuther M, et al. Protein mediated fatty acid uptake: synergy between CD36/FAT-facilitated transport and acyl-CoA synthetase-driven metabolism. Arch Biochem Biophys. 2014;546:8–18.PubMed
12.
go back to reference Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003;29:478–85.PubMed Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003;29:478–85.PubMed
13.
go back to reference Schwarz JM, Linfoot P, Dare D, et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2003;77:43–50.PubMed Schwarz JM, Linfoot P, Dare D, et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2003;77:43–50.PubMed
14.
go back to reference Kotronen A, Seppälä-Lindroos A, Vehkavaara S, et al. Liver fat and lipid oxidation in humans. Liver Int. 2009;29:1439–46.PubMed Kotronen A, Seppälä-Lindroos A, Vehkavaara S, et al. Liver fat and lipid oxidation in humans. Liver Int. 2009;29:1439–46.PubMed
15.
go back to reference Miele L, Grieco A, Armuzzi A, et al. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol. 2003;98:2335–6.PubMed Miele L, Grieco A, Armuzzi A, et al. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol. 2003;98:2335–6.PubMed
16.
go back to reference Nakamuta M, Kohjima M, Higuchi N, et al. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease. Int J Mol Med. 2008;22:663–7.PubMed Nakamuta M, Kohjima M, Higuchi N, et al. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease. Int J Mol Med. 2008;22:663–7.PubMed
17.
go back to reference Dasarathy S, Yang Y, McCullough AJ, et al. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23:382–8.PubMedPubMedCentral Dasarathy S, Yang Y, McCullough AJ, et al. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23:382–8.PubMedPubMedCentral
18.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMed Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMed
19.
go back to reference Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMed
20.
go back to reference Okushin K, Tsutsumi T, Enooku K, et al. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. J Gastroenterol. 2016;51:808–18.PubMed Okushin K, Tsutsumi T, Enooku K, et al. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. J Gastroenterol. 2016;51:808–18.PubMed
21.
go back to reference Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–50.PubMed Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–50.PubMed
22.
go back to reference Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359–68.PubMed Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359–68.PubMed
23.
go back to reference Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–10.PubMed Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–10.PubMed
24.
go back to reference Lee HW, Park SY, Kim SU, et al. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PLoS One. 2016;11:e0157358.PubMedPubMedCentral Lee HW, Park SY, Kim SU, et al. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PLoS One. 2016;11:e0157358.PubMedPubMedCentral
25.
go back to reference Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.PubMed Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.PubMed
26.
go back to reference Jungermann K. Metabolic zonation of liver parenchyma. Semin Liver Dis. 1988;8:329–41.PubMed Jungermann K. Metabolic zonation of liver parenchyma. Semin Liver Dis. 1988;8:329–41.PubMed
27.
go back to reference Enooku K, Kondo M, Fujiwara N, et al. Hepatic IRS1 and β-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol. 2018;53:1261–75.PubMedPubMedCentral Enooku K, Kondo M, Fujiwara N, et al. Hepatic IRS1 and β-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol. 2018;53:1261–75.PubMedPubMedCentral
28.
go back to reference Männistö VT, Simonen M, Hyysalo J, et al. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int. 2015;35:1853–61.PubMed Männistö VT, Simonen M, Hyysalo J, et al. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int. 2015;35:1853–61.PubMed
29.
go back to reference Gastaldelli A, Gaggini M, DeFronzo RA. Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio metabolism study. Diabetes. 2017;66:815–22.PubMed Gastaldelli A, Gaggini M, DeFronzo RA. Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio metabolism study. Diabetes. 2017;66:815–22.PubMed
30.
go back to reference Richieri GV, Kleinfeld AM. Unbound free fatty acid levels in human serum. J Lipid Res. 1995;36:229–40.PubMed Richieri GV, Kleinfeld AM. Unbound free fatty acid levels in human serum. J Lipid Res. 1995;36:229–40.PubMed
31.
go back to reference Stahl A, Gimeno RE, Tartaglia LA, et al. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab. 2001;12:266–73.PubMed Stahl A, Gimeno RE, Tartaglia LA, et al. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab. 2001;12:266–73.PubMed
32.
go back to reference Steneberg P, Sykaras AG, Backlund F, et al. Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. J Biol Chem. 2015;290:19034–43.PubMedPubMedCentral Steneberg P, Sykaras AG, Backlund F, et al. Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. J Biol Chem. 2015;290:19034–43.PubMedPubMedCentral
33.
go back to reference Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008;134:556–67.PubMed Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008;134:556–67.PubMed
34.
go back to reference Garbacz WG, Lu P, Miller TM, et al. Hepatic overexpression of CD36 improves glycogen homeostasis and attenuates high-fat diet-induced hepatic steatosis and insulin resistance. Mol Cell Biol. 2016;36:2715–27.PubMedPubMedCentral Garbacz WG, Lu P, Miller TM, et al. Hepatic overexpression of CD36 improves glycogen homeostasis and attenuates high-fat diet-induced hepatic steatosis and insulin resistance. Mol Cell Biol. 2016;36:2715–27.PubMedPubMedCentral
35.
go back to reference Martin GG, Danneberg H, Kumar LS, et al. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J Biol Chem. 2003;278:21429–38.PubMed Martin GG, Danneberg H, Kumar LS, et al. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J Biol Chem. 2003;278:21429–38.PubMed
36.
go back to reference Doege H, Grimm D, Falcon A, et al. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem. 2008;283:22186–92.PubMedPubMedCentral Doege H, Grimm D, Falcon A, et al. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem. 2008;283:22186–92.PubMedPubMedCentral
37.
go back to reference Zhu L, Baker SS, Liu W, et al. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism. 2011;60:1001–11.PubMed Zhu L, Baker SS, Liu W, et al. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism. 2011;60:1001–11.PubMed
38.
go back to reference Tsai JH, Ferrell LD, Tan V, et al. Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. Mod Pathol. 2017;30:834–42.PubMedPubMedCentral Tsai JH, Ferrell LD, Tan V, et al. Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. Mod Pathol. 2017;30:834–42.PubMedPubMedCentral
39.
go back to reference Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol. 2006;40(Suppl 1):S44–S50.PubMed Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol. 2006;40(Suppl 1):S44–S50.PubMed
40.
go back to reference Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242:610–7 (discussion 8–20).PubMedPubMedCentral Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242:610–7 (discussion 8–20).PubMedPubMedCentral
41.
go back to reference Müller MJ, Rieger A, Willmann O, et al. Metabolic responses to lipid infusions in patients with liver cirrhosis. Clin Nutr. 1992;11:193–206.PubMed Müller MJ, Rieger A, Willmann O, et al. Metabolic responses to lipid infusions in patients with liver cirrhosis. Clin Nutr. 1992;11:193–206.PubMed
42.
go back to reference Richardson RA, Davidson HI, Hinds A, et al. Influence of the metabolic sequelae of liver cirrhosis on nutritional intake. Am J Clin Nutr. 1999;69:331–7.PubMed Richardson RA, Davidson HI, Hinds A, et al. Influence of the metabolic sequelae of liver cirrhosis on nutritional intake. Am J Clin Nutr. 1999;69:331–7.PubMed
43.
go back to reference Horton JD, Bashmakov Y, Shimomura I, et al. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA. 1998;95:5987–92.PubMedPubMedCentral Horton JD, Bashmakov Y, Shimomura I, et al. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA. 1998;95:5987–92.PubMedPubMedCentral
Metadata
Title
Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients
Authors
Kenichiro Enooku
Takeya Tsutsumi
Mayuko Kondo
Naoto Fujiwara
Takayoshi Sasako
Junji Shibahara
Akira Kado
Kazuya Okushin
Hidetaka Fujinaga
Ryo Nakagomi
Tatsuya Minami
Masaya Sato
Koji Uchino
Hayato Nakagawa
Yuji Kondo
Yoshinari Asaoka
Ryosuke Tateishi
Kohjiro Ueki
Hitoshi Ikeda
Haruhiko Yoshida
Kyoji Moriya
Hiroshi Yotsuyanagi
Takashi Kadowaki
Kazuhiko Koike
Publication date
01-02-2020
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 2/2020
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01633-2

Other articles of this Issue 2/2020

Journal of Gastroenterology 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.